JCP
AMAG

Jabre Capital Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Jabre Capital Partners’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-80,216
Closed -$1.06M – 187
2017
Q4 		$1.06M Sell
80,216
-39,784
-33% -$600K 0.22% 78
2017
Q3 		$2.21M Buy
+120,000
New +$2.24M 0.43% 75

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jabre Capital Partners's AMAG Position: Q1 2018 in Review

Jabre Capital Partners sold out of AMAG Pharmaceuticals (AMAG) in Q1 2018, closing a stake of 80,216 shares — an estimated $1.06M sold.

Jabre Capital Partners first reported a position in AMAG in Q3 2017 and held it in 2 quarters. The position peaked at $2.21M in Q3 2017. 170 funds tracked by Wall St. Rank hold AMAG as of Q1 2018.

  • Jabre Capital Partners reported no remaining AMAG Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Jabre Capital Partners sold 80,216 AMAG Pharmaceuticals shares in Q1 2018, an estimated $1.06M.
  • Jabre Capital Partners first reported a position in AMAG Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Jabre Capital Partners's AMAG Pharmaceuticals position peaked at $2.21M in Q3 2017.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2018.

Based on Jabre Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.